KYMR logo

KYMERA THERAPEUTICS INC

KYMRNASDAQ
🏆 #928 by market capUS Equity
$110.51▼ $1.51 (−1.37%)
After hours · at close
🔔
Track KYMR
Get earnings, price moves & breaking news on Telegram
Track
24h▼ 1.4%
7d▼ 9.4%
14d▼ 2.3%
30d▼ 6.4%
ytd▲ 42.2%
1y▲ 88.9%
🏦Market Cap
$9.09B
Small Cap
📈Revenue Growth (YoY)
+134.8%
High Growth
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
88.7x
Expensive
Otter Score
56
Weak

Trading Snapshot

Day Range
$109.93 – $112.59
52-Week Range
$51.47 – $130.05
Volume
$3.25B
Avg Volume
$2.71B
Shares Outstanding
82.3M
Next Earnings
Nov 1, 2026

Fundamentals Snapshot

Annual Revenue
$105M
Last Q Revenue
$28M
P/E Ratio
—
P/S Ratio
88.7x
EPS (TTM)
$-3.24
Dividend Yield
—
Dilution (1yr)
+5.5%

Why Investors Own KYMR

  • ✓High-growth profile — revenue up +52.8% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 32% gross margin and 27% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

KYMR logo

KYMERA THERAPEUTICS INC

KYMR
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$39M▼ −16.7% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
100.0%▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$349M▲ +33.5% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$234M▲ +13.0% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
84.4M▲ +5.5% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$275M▲ +$242M YoY
StockOtter · stockotter.space

About KYMERA THERAPEUTICS INC

Kymera Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and developing pioneering small molecule therapeutics. These treatments operate by harnessing the body's inherent protein degradation system to selectively eliminate disease-causing proteins. The company's pipeline features several programs, including the IRAK4 program, currently in Phase I clinical trials, which targets various immunology-inflammation disorders such as hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, generalized pustular psoriasis, and rheumatoid arthritis. Additionally, Kymera is advancing its IRAKIMiD program, designed to address MYD88-mutated diffuse large B cell lymphoma. Other key programs include the STAT3 program, focused on hematological malignancies, solid tumors, autoimmune diseases, and fibrosis, as well as the MDM2 program, which is also aimed at hematological malignancies and solid tumors. The company was founded in 2015 and maintains its headquarters in Watertown, Massachusetts.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Weak
56/100

Analyst Price Target

ⓘ
Average Target
$141.24
▲ +27.8% Upside
High Target$159.35
Low Target$123.92
Based on 23 analysts

Latest News & Updates

🚀
MarketWatch·2h ago

KYMERA THERAPEUTICS INC tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
Bloomberg·5h ago

Analysts lift KYMR price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
Barron’s·1d ago

KYMERA THERAPEUTICS INC announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.